Allarity Therapeutics, Inc. (ALLR): who owns it and who trades it
As of Nov 12, 2026, no open-market insider purchases or sales of ALLR were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No ALLR insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ALLR short interest
Low short interest. 1.5% of ALLR shares are sold short: about 1 share in 69. Over the last 12 reports the number of shares short went down 22%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 230,750 ALLR shares were sold short, 1.5% of the shares outstanding, up 37.3% from the report before. At the average daily volume of 124,971 shares, buying them all back would take about 1.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 230,750 | 1.45% | +37% | 124,971 | 1.9 |
| Oct 15, 2026 | 168,026 | 1.06% | +41% | 121,140 | 1.4 |
| Sep 30, 2026 | 119,190 | 0.75% | +7% | 138,131 | 1.0 |
| Sep 15, 2026 | 111,895 | 0.70% | -7% | 111,461 | 1.0 |
| Aug 31, 2026 | 119,843 | 0.75% | +12% | 76,003 | 1.6 |
| Aug 14, 2026 | 106,564 | 0.67% | -12% | 88,277 | 1.2 |
| Jul 31, 2026 | 120,884 | 0.76% | -17% | 58,091 | 2.1 |
| Jul 15, 2026 | 145,807 | 0.92% | +80% | 139,949 | 1.0 |
| Jun 30, 2026 | 80,824 | 0.51% | -54% | 144,991 | 1.0 |
| Jun 15, 2026 | 175,384 | 1.11% | +0% | 185,530 | 1.0 |
| May 29, 2026 | 175,238 | 1.11% | -41% | 292,130 | 1.0 |
| May 15, 2026 | 296,872 | 1.88% | +8% | 287,201 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Allarity Therapeutics company events
Allarity Therapeutics filed 22 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 2, 2026.
- Nov 2, 2026AgreementAllarity Therapeutics, Inc. entered into a Settlement and Release Agreement with Novartis Pharma AG relating to an aggregate current liability of $4.9 million, plus interest, due to Novartis. Filing
- Oct 30, 2026AgreementEnded an important agreement. Filing
- Oct 1, 2026AnnouncementMade another announcement. Filing
- Sep 29, 2026AnnouncementMade another announcement. Filing
- Sep 16, 2026AnnouncementMade another announcement. Filing
- Sep 14, 2026AnnouncementMade another announcement. Filing
- Aug 14, 2026ResultsReleased financial results. Filing
- Jul 1, 2026AnnouncementThe Company announced that the United States Patent and Trademark Office (USPTO) has granted the key U.S. patent covering its proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. Filing
- Jun 22, 2026AnnouncementMade another announcement. Filing
- Jun 2, 2026LeadershipAs previously disclosed, effective June 1, 2024, Allarity Therapeutics, Inc., a Delaware corporation, entered into a Management Services Agreement with Ljungaskog Consulting AB, a Swedish limited liability company, owned and managed by Thomas H. Jensen, the Company’s Chief Executive Officer. Filing
- May 8, 2026AnnouncementThe Company announced that its Chief Executive Officer has been invited to speak at Precision Medicine Forum Europe 2026, to be held May 11–12, 2026, in Stockholm, Sweden. Filing
- May 6, 2026AnnouncementMade another announcement. Filing
- Apr 28, 2026AnnouncementMade another announcement. Filing
- Apr 22, 2026AnnouncementMade another announcement. Filing
- Apr 1, 2026ResultsReleased financial results. Filing
- Mar 9, 2026AnnouncementMade another announcement. Filing
- Mar 6, 2026AgreementAllarity Therapeutics, Inc., a Delaware corporation entered into a note purchase agreement with Streeterville Capital, LLC, a Utah limited liability company, pursuant to which the Company issued and sold to the Lender (i) a promissory note in the original principal amount of $10.93 million (the “… Filing
- Feb 19, 2026AnnouncementMade another announcement. Filing
- Feb 4, 2026AnnouncementMade another announcement. Filing
- Jan 29, 2026AgreementAllarity Therapeutics, Inc. entered into a Common Stock Purchase Agreement with Tumim Stone Capital LLC, a Delaware limited liability company. Filing
- Dec 23, 2025SharesSold new shares outside a public offering. Filing
- Dec 8, 2025LeadershipErvin December Employment Agreement As previously disclosed, in connection with the appointment of Mr. Jeffrey S. Ervin as Chief Financial Officer of Allarity Therapeutics, Inc., the Company and Mr. Ervin entered into an employment agreement dated July 1, 2025, pursuant to which Mr. Ervin began… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Allarity Therapeutics financials
Famous investors that hold ALLR
1 of the 50 well-known investors we track reported holding ALLR in their latest 13F filing. The largest position is Jim Simons's, worth $320K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 304,800 | $320K | 0.0% | -8% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Allarity Therapeutics, Inc. (ALLR) stock
Are ALLR insiders buying or selling?
No ALLR insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in ALLR?
As of Oct 30, 2026, 230,750 ALLR shares were sold short, 1.5% of the shares outstanding, up 37.3% from the report before. At the average daily volume of 124,971 shares, buying them all back would take about 1.9 trading days (days to cover). See the history.
Which famous investors hold ALLR?
1 of the 50 well-known investors we track reported ALLR in their latest 13F filing, including Jim Simons. The largest position is worth $320K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.